Paper - WANFANG MED ONLINE

You Position: Home > Paper

卵巢肿瘤心脏病学的研究现状及展望

( views:9, downloads:9 )

Author:: No author available

Journal Title:: Journal of Practical Obstetrics and Gynecology

Issue:: 1

DOI:: No doi available

Key Word:: 卵巢癌;心血管疾病;肿瘤心脏病学

Abstract：肿瘤心脏病学为一门新兴的交叉学科,卵巢癌相关心血管事件逐渐成为卵巢癌幸存者重要的健康隐患,肿瘤心脏病学在卵巢癌中应引起重视.卵巢癌导致心血管疾病,心血管疾病促进卵巢癌的发生、发展,并影响卵巢癌的治疗决策及生存,且二者具有共同的风险因素,此外,卵巢癌手术、化疗、靶向治疗均可能导致心血管损伤,在卵巢癌抗肿瘤治疗前,应识别和治疗心血管危险因素,并制定适当的预防及监测计划.本文综述了卵巢癌与心血管疾病相关性、卵巢癌治疗相关心血管损伤及其临床管理与预防策略,以期提高妇瘤医生对卵巢癌相关心血管疾病的重视,与心血管病专家建立合作关系,为卵巢癌及其相关的心血管疾病制定合理的诊疗流程,从而达到改善卵巢癌预后的最终目的.

Reference

[1]Sammy, Zakaria,Kit Yu, Lu,Veronique, Nussenblatt,etc.Atrial flutter associated with carboplatin administration.[J].2011,45(11).
[2]卢淮武,叶栋栋,吴斌,等.《2023 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南（第1版）》解读[J].2023,39(1).
[3]温灏.PARP抑制剂不良反应管理的中国专家共识（2021年版）[J].2021,(11).
[4]Herrmann Joerg.Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia[J].2020,17(8).
[5]Zhai, Zijing,Qin, Wenjuan,Wang, Zhen,etc.Changes in left ventricular function induced by carboplatin combined with paclitaxel in patients with ovarian cancer identified using three-dimensional spot tracking imaging technology[J].2021,49(4).
[6]Farzad, Masoudkabir,Nizal, Sarrafzadegan,Carolyn, Gotay,etc.Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention.[J].2017,263(Spec ).
[7]蒋芳,向阳.卵巢癌免疫治疗的现状与进展[J].2021,(6).
[8]Ferriss,J.S.,Ring,K.,King,E.R.,etc.Does significant medical comorbidity negate the benefit of up-front cytoreduction in advanced ovarian cancer?[J].2012,22(5).
[9]杨昌瑞,狄文.卵巢上皮性癌相关静脉血栓栓塞的危险因素及防治的研究进展[J].2022,57(9).
[10]E Andreopoulou,D Gaiotti,E Kim,etc.Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer[J].2007,18(4).
[11]Kong Joseph C.,Peacock Oliver,Waters Peadar S.,etc.Predictors of overall survival following extended radical resections for locally advanced and recurrent pelvic malignancies[J].2020,405(4).
[12]Savant, Sudha S.,Sriramkumar, Shruthi,O’Hagan, Heather M..The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer[J].2018,10(8).
[13]Jose Luis, Zamorano,Patrizio, Lancellotti,Daniel Rodriguez, Mu?oz,etc.[2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines].[J].2016,(11).
[14]de Boer Rudolf A.,Aboumsallem Joseph Pierre,Bracun Valentina,etc.A new classification of cardio-oncology syndromes[J].2021,7(1).
[15]Coster E,Linsen MA,Yeung KK,etc.Repeated arterial thrombosis as a complication of carboplatin-based chemotherapy.[J].2006,14(1).
[16]中华医学会妇科肿瘤学分会.妇科恶性肿瘤聚乙二醇化脂质体多柔比星临床应用专家共识[J].2020,(7).
[17]Joseph Pierre,Aboumsallem,Javid,Moslehi,Rudolf A,de Boer.Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease.[J].2020,9(2).
[18]中国抗癌协会妇科肿瘤专业委员会.中国卵巢上皮性癌维持治疗指南（2022年版）[J].2022,38(1).
[19]Kushnir, C. L.,Angarita, A. M.,Havrilesky, L. J.,etc.Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD)[J].2015,137(3).
[20]Maryska L.G. Janssen-Heijnen,Saskia Houterman,Valery E.P.P. Lemmens,etc.Prognostic impact of increasing age and co-morbidity in cancer patients: A population-based approach[J].2005,55(3).
[21]Tanaka H,Ito M,Yoshida K.Nonbacterial thrombotic endocarditis complicated with stage Ia ovarian cancer.[J].2009,14(4).
[22]Singh,K.K.,Shukla,P.C.,Yanagawa,B.,etc.Regulating cardiac energy metabolism and bioenergetics by targeting the DNA damage repair protein BRCA1[J].2013,146(3).
[23]Chia-Ming,Yang,Mu-Yang,Hsieh,Lin,Lin,etc.Acute Myocardial Infarction in Association with Occult Ovarian Cancer.[J].2013,29(1).
[24]Ngo, Doan T. M.,Williams, Trent,Horder, Sophie,etc.Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab[J].2020,9(8).